Latest News and Press Releases
Want to stay updated on the latest news?
-
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
-
Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A...
-
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
-
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
-
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
-
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025...
-
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
-
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
-
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
-
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update